Next Article in Journal
Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy
Next Article in Special Issue
Bioapplications of Cell-SELEX-Generated Aptamers in Cancer Diagnostics, Therapeutics, Theranostics and Biomarker Discovery: A Comprehensive Review
Previous Article in Journal
Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics
Previous Article in Special Issue
Current Advances in Aptamers for Cancer Diagnosis and Therapy
Open AccessReview

EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs

School of Medicine, Deakin University, Geelong, VIC 3128, Australia
Centre for Comparative Genomics, Murdoch University, Perth, WA 6150, Australia
Perron Institute for Neurological and Translational Science, Perth, WA 6009, Australia
Department of Pathology and University of Melbourne, Melbourne, VIC 3010, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia
Matrix Microenvironment and Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, VIC 3084, Australia
Centre for Molecular and Medical Research, Deakin University, Geelong, VIC 3128, Australia
Author to whom correspondence should be addressed.
Cancers 2018, 10(1), 19;
Received: 18 December 2017 / Revised: 8 January 2018 / Accepted: 8 January 2018 / Published: 12 January 2018
(This article belongs to the Special Issue Aptamers: Promising Tools for Cancer Diagnosis and Therapy)
The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not shown as much promise as initially heralded. In this review, we look at the reasons why and consider alternative targeting options, such as aptamers, to turn this almost ubiquitously expressed epithelial cancer biomarker into a viable target for future personalized therapy. View Full-Text
Keywords: antibody; aptamer; cancer; EpCAM; immunotherapy; therapeutics antibody; aptamer; cancer; EpCAM; immunotherapy; therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Macdonald, J.; Henri, J.; Roy, K.; Hays, E.; Bauer, M.; Veedu, R.N.; Pouliot, N.; Shigdar, S. EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. Cancers 2018, 10, 19.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop